UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The burden of bleeding in haemophilia: is one bleed too many?

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-07, Vol.20 (4), p.459-463

2014

Volltextzugriff (PDF)

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Journal of thrombosis and haemostasis, 2009-03, Vol.7 (3), p.413-420

2009

Volltextzugriff (PDF)

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

Journal of thrombosis and haemostasis, 2010-02, Vol.8 (2), p.269-275

2010

Volltextzugriff (PDF)

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-03, Vol.21 (2), p.162-170

2015

Volltextzugriff (PDF)

Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.615-624

2016

Volltextzugriff (PDF)

The role of previously untreated patient studies in understanding the development of FVIII inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.22-31

2016

Volltextzugriff (PDF)

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

Journal of thrombosis and haemostasis, 2010-04, Vol.8 (4), p.730-736

2010

Volltextzugriff (PDF)

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.65-72

2014

Volltextzugriff (PDF)

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.514-520

2016

Volltextzugriff (PDF)

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-05, Vol.17 (3), p.412-421

2011

Volltextzugriff (PDF)

Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease

Journal of blood medicine, 2022-11, Vol.13, p.649-662

2022

Volltextzugriff (PDF)

FEIBA® safety profile in multiple modes of clinical and home-therapy application

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-09, Vol.10 (s2), p.10-16

2004

Volltextzugriff (PDF)

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Thrombosis and haemostasis, 1998-12, Vol.80 (6), p.912-918

1998

Volltextzugriff (PDF)

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

Haemophilia : the official journal of the World Federation of Hemophilia, 2010-11, Vol.16 (6), p.866-877

2010

Volltextzugriff (PDF)

Emerging clinical concerns in the ageing haemophilia patient

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-11, Vol.15 (6), p.1197-1209

2009

Volltextzugriff (PDF)

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-05, Vol.17 (3), p.433-438

2011

Volltextzugriff (PDF)

Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®)

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-01, Vol.10 (1), p.42-51

2004

Volltextzugriff (PDF)

Central venous access devices in haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-03, Vol.10 (2), p.134-146

2004

Volltextzugriff (PDF)

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-09, Vol.10 (5), p.428-437

2004

Volltextzugriff (PDF)

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2007-05, Vol.13 (3), p.256-263

2007

Volltextzugriff (PDF)

Consensus recommendations for use of central venous access devices in haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2004-09, Vol.10 (5), p.629-648

2004

Volltextzugriff (PDF)

Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-09, Vol.17 (5), p.e847-e848

2011

Volltextzugriff (PDF)

Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy

Haemophilia : the official journal of the World Federation of Hemophilia, 2003-11, Vol.9 (6), p.688-695

2003

Volltextzugriff (PDF)

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper

Blood, 2000-09, Vol.96 (5), p.1698-1702

2000

Volltextzugriff (PDF)

Regulated secretion in endothelial cells: biology and clinical implications

Thrombosis and haemostasis, 2001-11, Vol.86 (5), p.1148-1155

2001

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(113)

Publikationsform

Sprache

Englisch
(142)
Japanisch
(14)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The burden of bleeding in haemophilia: is one bleed too many?

Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy

The role of previously untreated patient studies in understanding the development of FVIII inhibitors

Comparative pharmacokinetics of plasma‐ and albumin‐free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age‐related differences and implications for dose tailoring

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis

The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study

Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease

FEIBA® safety profile in multiple modes of clinical and home-therapy application

Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

Emerging clinical concerns in the ageing haemophilia patient

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials

Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®)

Central venous access devices in haemophilia

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors

Consensus recommendations for use of central venous access devices in haemophilia

Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study

Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy

Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper

Regulated secretion in endothelial cells: biology and clinical implications

Suchergebnisse filtern